The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Abstract

Background Worldwide, both the incidence and death rates of pancreatic cancer are increasing. Evaluation of pancreatic cancer burden and its global, regional, and national patterns is crucial to policy making and better resource allocation for controlling pancreatic cancer risk factors, developing early detection methods, and providing faster and more effective treatments. Methods Vital registration, vital registration sample, and cancer registry data were used to generate mortality, incidence, and disability-adjusted life-years (DALYs) estimates. We used the comparative risk assessment framework to estimate the proportion of deaths attributable to risk factors for pancreatic cancer: smoking, high fasting plasma glucose, and high body-mass index. All of the estimates were reported as counts and age-standardised rates per 100 000 person-years. 95% uncertainty intervals (UIs) were reported for all estimates. Findings In 2017, there were 448 000 (95% UI 439 000-456 000) incident cases of pancreatic cancer globally, of which 232 000 (210 000-221 000; 51•9%) were in males. The age-standardised incidence rate was 5•0 (4•9-5•1) per 100 000 person-years in 1990 and increased to 5•7 (5•6-5•8) per 100 000 person-years in 2017. There was a 2•3 times increase in number of deaths for both sexes from 196 000 (193 000-200 000) in 1990 to 441 000 (433 000-449 000) in 2017. There was a 2•1 times increase in DALYs due to pancreatic cancer, increasing from 4•4 million (4•3-4•5) in 1990 to 9•1 million (8•9-9•3) in 2017. The age-standardised death rate of pancreatic cancer was highest in the highincome super-region across all years from 1990 to 2017. In 2017, the highest age-standardised death rates were observed in Greenland (17•4 [15•8-19•0] per 100 000 person-years) and Uruguay (12•1 [10•9-13•5] per 100 000 personyears). These countries also had the highest age-standardised death rates in 1990. Bangladesh (1•9 [1•5-2•3] per 100 000 person-years) had the lowest rate in 2017, and São Tomé and Príncipe (1•3 [1•1-1•5] per 100 000 personyears) had the lowest rate in 1990. The numbers of incident cases and deaths peaked at the ages of 65-69 years for males and at 75-79 years for females. Age-standardised pancreatic cancer deaths worldwide were primarily attributable to smoking (21•1% [18•8-23•7]), high fasting plasma glucose (8•9% [2•1-19•4]), and high body-mass index (6•2% [2•5-11•4]) in 2017. Interpretation Globally, the number of deaths, incident cases, and DALYs caused by pancreatic cancer has more than doubled from 1990 to 2017. The increase in incidence of pancreatic cancer is likely to continue as the population ages. Prevention strategies should focus on modifiable risk factors. Development of screening programmes for early detection and more effective treatment strategies for pancreatic cancer are needed. Funding Bill & Melinda Gates Foundation.

Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: A retrospective multicenter cohort study

“…The present study showed that most UC patients were diagnosed at the age of 60-70 years, with a slight male predominance. These clinical features were similar to those of PC [2] [23] [24]. It has been reported that UC of the pancreas expressed epithelial-mesenchymal transition (EMT) markers (e.g.…”

“…It has been estimated that, in 2020, approximately 47,050 patients will die of this disease [1]. Global data showed that 448,000 patients were diagnosed with PC in 2017, with a 2.3-times increase in the number of incident cases and deaths from 1990 to 2017 [2]. Despite efforts to develop new treatments [3] [4], the prognosis of PC patients remains poor, and the morbidity is increasing.…”

E-Cadherin in Pancreatic Ductal Adenocarcinoma: A Multifaceted Actor during EMT

“…PDAC represents the fourth most common cause of cancer death in the Western world, with an estimated incidence of more than 40,000 cases per year in the United States and 448,000 cases globally. It is one of the most devastating, aggressive and lethal tumors, characterized by a 5-year survival for all stages of the disease <7% [2][3][4], due to the high incidence of recurrence and metastases dissemination [5].…”

Effectiveness of introducing a 20-gauge core biopsy needle with a core trap in EUS-FNA/B for diagnosing pancreatic cancer

“…The age-standardized incidence rate of pancreatic cancer increased by 1.03% per year from 1973 to 2014 [6]. Changes in environmental and behavioral factors rather than genetic factors are thought to be related to the worldwide increase in pancreatic cancer [7].…”

“…The incidence is signi cantly different among geographical areas; the highest incidence is found in Europe and North America, while the lowest is found in Africa and South Central Asia [8]. Differences in lifestyle (e.g., high-calorie diet and high body mass index), exposure to environmental risk factors (e.g., smoking), and accessibility to medical services including more e cient diagnostic tools might be associated with the variability in the mortality of pancreatic cancer among countries [7,9,10]. A recent study showed that pancreatic cancer is ranked as the 14th most common cancer and the 7th most common cause of cancer mortality worldwide [8]; however, the socioeconomic burden of pancreatic cancer is expected to increase globally in the near future.…”